CTI Life Sciences Fund related stories
All articles and analysis
Fonds de solidarité FTQ puts $5.75 mln to work in ImmunovaccineFonds de solidarité FTQ has invested $5.75 million in Immunovaccine Inc (TSX: IMV), a clinical-stage biopharmaceutical company with offices and labs in Halifax and Québec City. The investment was made through a $14.4 million bought deal offering closed last week. Founded in 2000, Immunovaccine develops cancer immunotherapies and infectious disease vaccines using DepoVax, a proprietary drug release platform. Led by President and CEO Frédéric Ors, the company will use the funds raised for R&D to further advance its product pipeline. Immunovaccine's other Canadian investors include CTI Life Sciences Fund.
PHEMI closes $10 mln financing with new and existing VCsCanadian big data warehouse company PHEMI Inc has raised $10 million in follow-on financing. CTI Life Sciences Fund, BDC Capital and Yaletown Partners, which participated in PHEMI’s $12.2 million Series A financing in 2015, co-led the latest round. They were joined by new investors Quark Venture and GF Securities Co Ltd. Founded in 2013, PHEMI helps data-driven businesses in life sciences and other sectors to unlock and share information without compromising privacy.
PHEMI closes $10 mln financing with new and existing VCsVancouver big data warehouse company PHEMI Inc has raised $10 million in follow-on financing. CTI Life Sciences Fund, BDC Capital and Yaletown Partners, which participated in PHEMI's $12.2 million Series A financing in 2015 /canada/?p=320985 co-led the latest round. They were joined by new investors Quark Venture and GF Securities Co Ltd. Founded in 2013, PHEMI helps data-driven businesses in life sciences and other sectors to unlock and share information without compromising privacy. Led by CEO Paul Terry, the company will use the funds raised to expand commercialization through expanded sales and marketing and outreach into emerging vertical markets.
Biotech boom continues with Repare’s $90 mln Series A, Zymeworks IPOCanada’s life sciences sector is on a roll. Current levels of venture capital investment are unprecedented. This week another major deal was announced, with Repare Therapeutics, a Montréal developer of precision oncology drugs, securing about $90 million in a Series A financing. One of the sector’s other big stories is the IPO of biotherapeutics provider Zymeworks. The company, which last month raised about $86 million on the Toronto and New York exchanges, is now being talked about as Canada’s next biotech anchor company.
Venture-backed Zymeworks tops up IPO raise to $86 mlnZymeworks Inc (NYSE, TSX: ZYME) has raised additional proceeds from its initial public offering /canada/2017/4/vc-backed-zymeworks-targets-110-mln-from-tsx-nyse-ipo/ in Canada and the United States with the partial exercise of the over-allotment option. In total, the Vancouver biotherapeutics provider secured about $86 million (US$63.6 million). Zymeworks earlier said the proceeds will be used to further advance the company’s pipeline of product candidates and increase liquidity. Launched in 2003, Zymeworks is backed /canada/2016/1/zymeworks-scores-61-5-mln-series-a/ by multiple venture capital and strategic investors, including BDC Capital, Celgene, CTI Life Sciences Fund, Eli Lilly & Co and Lumira Capital.
BDC's Dion Madsen, CTI's Shermaine Tilley depart Zymeworks boardShermaine Tilley, a managing partner at CTI Life Sciences Fund, and Dion Madsen, a senior managing partner at BDC Capital, have left the board of directors of Zymeworks Inc (NYSE, TSX: ZYME). The resignations, which also included Eli Lilly & Co's Kerry Blanchard, follow Zymeworks' initial public offering in Canada and the United States, which wrapped up earlier this month /canada/2017/5/3451188/ Vancouver-based Zymeworks, a biotherapeutics provider, went public after raising nearly /canada/2017/4/vc-backed-zymeworks-targets-110-mln-from-tsx-nyse-ipo/ US$150 million from a mix of venture capital and strategic investors.
Zymeworks' IPO raises $80 mln, greenshoe option to comeVancouver-based biotherapeutics provider Zymeworks Inc (NYSE, TSX: ZYME) has wrapped up its initial public offering in Canada and the United States, raising about $80 million (US$58.5 million). Zymeworks has granted underwriters an over-allotment option to purchase additional shares, which may bring the total to more than $110 million /canada/2017/4/vc-backed-zymeworks-targets-110-mln-from-tsx-nyse-ipo/ The proceeds will be used to further advance the company's pipeline of product candidates and increase liquidity. Founded in 2003, Zymeworks is backed /canada/2016/1/zymeworks-scores-61-5-mln-series-a/ by multiple venture capital and strategic investors, including BDC Capital, Celgene, CTI Life Sciences Fund, Eli Lilly & Co and Lumira Capital.
- VC-backed Zymeworks rolls out New York and Toronto IPO
Vancouver, British Columbia-based biotherapeutics provider Zymeworks Inc has raised $58.5 million for its IPO after pricing its 4.5 million shares at $13 per share. The stock began trading April 28, 2017 on the New York Stock Exchange and on the Toronto Stock Exchange under the ticker symbol “ZYME."Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are the lead underwriters. Zymeworks' pre-IPO backers include BDC Capital, Lumira Capital, CTI Life Sciences Fund, Fonds de solidarité FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus.
